Banned Cosmetic Ingredients EU: The 2026-2027 Reformulation Schedule

If you sell into the EU, the list of banned cosmetic ingredients EU regulators maintain is not the document that will cost you money. The document that costs you money is the one nobody writes for you: the reformulation schedule. Annex II of Regulation (EC) No 1223/2009 now runs past 1,700 prohibited substances, and between September 2025 and June 2027 four separate instruments change what you are allowed to ship. Each one maps to a replacement ingredient, a new stability run, and a decision about whether your Product Information File needs reopening.

We run 13 production lines under ISO 22716 and GMPC certification, and most of the EU-bound enquiries we handle in 2026 arrive the same way: a brand forwards a compliance flag from their Responsible Person, asks what it means for their existing SKU, and wants to know how long a fix takes. This guide answers the second question, because the first one is already covered well by regulatory consultancies. What follows is the manufacturing side.

The four deadlines that actually change your formula

Four regulations govern the current wave. They stack, which is the part brands underestimate — a single anti-dandruff shampoo with a retinol claim and a fragrance can touch three of them at once.

Date	Regulation	What changes	Transition
1 Sep 2025	Regulation (EU) 2025/877 (Omnibus VII)	New CMR substances prohibited, including triclocarban, climbazole and 2-chloroacetamide	None — existing stock also unsellable
1 Nov 2025	Regulation (EU) 2024/996	Vitamin A capped at 0.3% RE (0.05% in body lotion); alpha-arbutin capped at 2% on face	New placements only
31 Jul 2026	Regulation (EU) 2023/1545	Fragrance allergen labelling expands from 26 to 82 substances	New products from this date
Jun 2027	Regulation (EU) 2024/1328 (REACH Annex XVII)	D4/D5/D6 cyclic siloxanes capped at 0.1% in all cosmetics, not just rinse-off	36 months from Jun 2024
1 May 2027	Regulation (EU) 2024/996	Existing non-compliant vitamin A stock must be off shelves	Final withdrawal
31 Jul 2028	Regulation (EU) 2023/1545	All products, including existing stock, must carry expanded allergen labelling	Final withdrawal

Two of those rows have no transition period at all, and that distinction decides your response. A capped ingredient gives you a runway to reformulate at your next production cycle. A CMR ban does not — it invalidates finished goods sitting in a Rotterdam warehouse.

Omnibus VII: the ban with no grace period

Regulation (EU) 2025/877 took effect on 1 September 2025 and added a set of substances newly classified as carcinogenic, mutagenic or toxic for reproduction under CLP. Article 15 of the Cosmetics Regulation makes CMR classification an automatic prohibition trigger unless a narrow derogation is granted, and none was granted here.

Three of the listed substances matter for volume personal care:

• Climbazole — an antifungal used in anti-dandruff shampoos and scalp treatments, typically at 0.5% to 1.0% in rinse-off formats. This is the one that surprised the most brands, because climbazole was a workhorse in the category. Our own anti-dandruff oil-control shampoo runs a piroctone olamine system for this reason.
• Triclocarban — antibacterial agent in cleansing bars and body washes. Already restricted in several markets, so exposure here is lower.
• 2-Chloroacetamide — a preservative. Uncommon in modern formulas but occasionally present in legacy formulations that have not been reviewed in a decade.

What replaces climbazole

There is no single drop-in substitute, and any factory telling you otherwise has not run the challenge testing. The practical routes we use depend on whether the brand needs to keep an anti-dandruff efficacy claim:

• Piroctone olamine — the closest functional equivalent, permitted under Annex III entry 24 at 1.0% in rinse-off hair products and 0.5% in leave-on. Efficacy against Malassezia is well documented, and it holds up in the pH range most shampoo bases sit in.
• Zinc pyrithione — still permitted for rinse-off hair products under Annex III, but its own regulatory position has moved repeatedly across markets, so we generally advise against building a new range around it in 2026.
• Salicylic acid at rinse-off levels — works for scaling and buildup rather than fungal load. Suitable when the brand is willing to reposition the claim from anti-dandruff to scalp exfoliation, which also sidesteps the treatment-claim problem in the EU. A scalp care refreshing hair mask is the format we most often pair with this repositioning.

The reformulation is not cosmetic. Swapping climbazole for piroctone olamine changes the preservative load balance and often the final pH target, which means the previous stability data no longer applies. Plan for a fresh accelerated run.

Vitamin A: a cap, not a ban, and the difference matters

Regulation (EU) 2024/996 restricts vitamin A and its common derivatives — retinol, retinyl acetate and retinyl palmitate — based on the SCCS opinion adopted in October 2022. The limits are expressed as Retinol Equivalent, which is the detail brands most often get wrong.

Product type	Maximum
Face products, other leave-on and rinse-off	0.3% RE
Body lotion	0.05% RE
Lip products, oral spray, sunscreen	0.05% RE

Products placed on the market from 1 November 2025 must comply. Everything still on shelves must be compliant by 1 May 2027. Any product containing vitamin A derivatives also needs the warning statement "Contains Vitamin A. Consider your daily intake before use" on the label — a packaging artwork change, not just a formula change, and artwork lead times are frequently the longer of the two.

Retinol Equivalent is a conversion, not a raw percentage. Retinyl palmitate at 1.0% does not contribute 1.0% RE, because the ester carries more molecular weight per active retinol unit. Factories that quote you a compliant number without stating which derivative and which conversion factor they used are guessing. Ask for the calculation.

Reformulating a retinol range for the 0.3% ceiling

Most premium retinol serums built for the US market sit at 0.5% to 1.0% retinol, which puts them straight over the EU line. Three routes out:

• Reduce and support. Drop retinol to within 0.3% RE and rebuild perceived performance with adjacent actives — bakuchiol, peptides, or niacinamide — that carry no vitamin A restriction. This is the least disruptive path when the brand can accept a repositioned claim.
• Switch to retinal (retinaldehyde). Also a vitamin A derivative and also counted toward the RE cap, so this does not create headroom. It is worth considering only for stability or tolerance reasons, not compliance reasons. We flag this because several brands have arrived assuming retinal was outside scope.
• Move to a non-vitamin-A alternative entirely. Bakuchiol, and the newer generation of retinol-adjacent actives, sit outside Regulation (EU) 2024/996. Our breakdown of current active ingredient trends covers what is realistically available at OEM volumes and what is still marketing-led.

The same regulation caps alpha-arbutin at 2.0% in face products and 0.5% in body products. That cap is a safety ceiling set by the SCCS, not a performance optimum — a distinction we hold to on every brightening formula we quote, because the two get conflated constantly. If your current supplier is running alpha-arbutin above 2% in a face serum destined for the EU, that formula was already non-compliant before this wave of changes. We hold to the 2% ceiling across brightening formulas including our glutathione brightening serum, and state a baseline and range rather than a fixed figure so the level can be set against your destination market.

D4, D5 and D6: the 2027 problem hiding in your hair care line

Regulation (EU) 2024/1328 amended Annex XVII of REACH to cap cyclotetrasiloxane (D4), cyclopentasiloxane (D5) and cyclohexasiloxane (D6) at 0.1% by weight — individually — across all cosmetic products. The previous restriction covered wash-off products only. The compliance date is June 2027, 36 months after entry into force in June 2024.

ECHA classified these as substances of very high concern on persistence grounds (PBT and vPvB), which is why the restriction came through REACH rather than the Cosmetics Regulation. The practical consequence is that many brands have not seen it flagged, because their Responsible Person is watching Annex II and Annex III, not Annex XVII.

Where the exposure sits, in our order of severity:

• Leave-on hair serums and heat protectants. D5 has historically been used at 5% to 20% in this category as the primary volatile carrier. There is no version of this reformulation that is a small tweak. Leave-on formats such as our deep nourish leave-in conditioner sit directly in scope from June 2027.
• Primers and long-wear colour cosmetics. Cyclic siloxanes deliver the dry, slip-forward feel this category is built on. Replacing them changes the sensory profile in a way consumers notice.
• Antiperspirants and dry-touch sunscreens. Same mechanism, same problem.
• Conditioners and rinse-off treatments. Lower exposure, since the old rinse-off restriction already pushed most formulas below the threshold.

What we substitute for D5

• Linear volatile silicones — hexamethyldisiloxane and low-viscosity dimethicone grades sit outside the cyclic restriction and reproduce much of the volatility and dry-down. Closest match on feel.
• Isododecane and isohexadecane — hydrocarbon volatiles, widely used in colour cosmetics. Good spreadability, different residue profile, and they interact differently with pigments and film formers.
• C13-16 isoparaffin and similar esters — for formulas where the goal is emollient slip rather than volatility.

None of these is a like-for-like swap on sensory profile. The honest position is that a D5-free heat protectant feels different from a D5 one, and the reformulation work is mostly in getting the difference to an acceptable place rather than eliminating it. Brands that budget one sampling round for this are usually wrong; two to three is realistic.

Fragrance allergens: 82 substances, and it is a labelling problem first

Regulation (EU) 2023/1545 expands the list of fragrance allergens requiring individual declaration on the ingredient list from 26 substances to 82. New products must comply from 31 July 2026; existing products have until 31 July 2028.

The disclosure thresholds are unchanged: 0.001% in leave-on products and 0.01% in rinse-off products. What changed is how many substances trip them. A single natural essential oil can contain a dozen of the newly listed allergens as constituents — which means the ingredient list on a lavender body lotion may go from three declared allergens to eleven, without a single change to the formula. Fragrance-forward products carry the heaviest declaration load; our eau de toilette range is where we see the longest allergen statements.

This is the change most likely to catch brands who assume "natural fragrance" is the safe route. It is not, from a labelling standpoint. Essential oils carry more declarable constituents than most synthetic fragrance compounds, and the new list makes that gap wider.

The OEM response, in order

1. Get an updated allergen breakdown from your fragrance house. Not the old 26-allergen certificate — the full IFRA-format statement against the 82-substance list. Most reputable suppliers have issued these; some smaller houses have not, and that is a supplier problem you want to find in 2026 rather than 2028.
2. Decide whether to relabel or reformulate. If the expanded declaration makes the ingredient list unwieldy or undermines a clean-beauty positioning, reformulating the fragrance to drop below thresholds is an option. It is usually cheaper than it sounds, because fragrance houses can rebuild a scent profile around constrained inputs.
3. Sequence the artwork change with a production run. Relabelling outside a scheduled run means paying for a packaging change twice.

For brands running multi-market ranges, note that this diverges from US requirements, where fragrance can still largely be declared as a single "fragrance" entry. A shared label across both markets is no longer realistic for scented products.

Cosmetic ingredients banned in Europe but not the US

The gap is large and frequently misrepresented in both directions. The accurate framing: Annex II of Regulation (EC) No 1223/2009 lists over 1,700 prohibited substances, while US federal law has historically prohibited or restricted around 11. That comparison is real, but it does not mean US products are unregulated — it means the two systems restrict differently.

The EU operates a precautionary, list-based prohibition system: a substance classified as CMR is banned by default under Article 15. The US, under FD&C authority, has relied on a general safety standard with few explicit prohibitions. MoCRA, signed in December 2022 and still phasing in, introduces mandatory facility registration, product listing and safety substantiation — closing part of the gap on process, though not by producing a long prohibition list. We cover the current filing obligations in our MoCRA compliance guide for cosmetics brands.

The substances that most often create a genuine EU/US divergence in the formulas we are asked to quote:

Substance	EU status	US status	OEM consequence
Hydroquinone	Prohibited in cosmetics (Annex II)	Permitted OTC at 2% for skin lightening	Two separate formulas required; no shared SKU possible
Climbazole	Prohibited from Sep 2025 (Reg. 2025/877)	Permitted	Split anti-dandruff range or reformulate globally
Retinol above 0.3% RE	Restricted (Reg. 2024/996)	No concentration limit	EU-specific strength tier
D4/D5/D6 above 0.1%	Restricted from Jun 2027 (Reg. 2024/1328)	Permitted	Regional formula split or global reformulation
Certain sunscreen filters	Approved list differs by market	Narrower approved list than EU	See our market-by-market sunscreen filter comparison

The operational question is whether to run one global formula at the strictest common denominator, or regional variants. Our default advice: single formula for anything you can build compliantly for the EU without losing the product, regional split only where the EU restriction removes the product's reason to exist — a 2% hydroquinone lightener has no compliant EU version, so there is nothing to harmonise. The EU-legal route to the same brief is a different active system, which is what sits behind our niacinamide brightening anti-spot cream.

Running to the EU standard globally costs slightly more per unit and saves substantially on documentation, warehousing and the risk of the wrong pallet reaching the wrong port. For brands under roughly five SKUs, the harmonised route is almost always the cheaper total.

What reformulating actually takes: the schedule nobody quotes you

This is where the regulatory guides stop and the manufacturing question starts. A compliance flag is not a formula change; it is the start of a sequence with a real duration. Here is how the work breaks down on our lines for a standard emulsion or aqueous formula.

Stage	Duration	What happens
Formula assessment	3–5 working days	Screen the existing INCI list against Annexes II, III and REACH Annex XVII; identify which restriction applies and whether a cap or a prohibition is in play
Substitution and lab trials	2–3 weeks	Bench trials of the replacement system; pH, viscosity and sensory adjustment; preservative efficacy re-check where the change affects the system
Sample approval	1–2 weeks	Client evaluation, usually one revision round; two to three rounds where sensory profile is central, as with D5 replacement
Accelerated stability	4–6 weeks	Elevated temperature and cycling protocols; runs in parallel with artwork and documentation work
Documentation update	Parallel	Updated specifications and supporting data for the Responsible Person to revise the Product Information File

Total realistic window: 45 to 60 days from brief to production-ready formula, for a standard cream, lotion, serum or cleanser. Formats that need extended testing — anhydrous balms, high-oil systems, anything with an SPF claim — run longer, and we quote those separately rather than compressing them.

Two things shorten this materially. First, we hold an existing library of EU-compliant base formulas across cleansers, serums, creams, body care and hair care, so most substitutions start from a validated base rather than a blank sheet. Second, running assessment and lab trials concurrently for multiple SKUs from the same range shares most of the trial work — a five-SKU range does not take five times as long as one.

What does not compress is accelerated stability. A four-to-six week protocol is a four-to-six week protocol, and a factory offering to skip it or shorten it to hit your date is handing you a shelf-life risk in exchange for a calendar win. If you want to understand what a credible report contains, we walk through it in how to read a cosmetic stability testing report.

MOQ during a reformulation

Reformulation is one of the few situations where we routinely recommend a smaller first run than the brand wants to order. Produce a compliance-verification batch, get it through your Responsible Person's review and your own market check, then scale. The alternative — committing full volume to a reformulated product before the documentation is signed off — is how brands end up with compliant stock they cannot sell for a different reason, usually an artwork or claims issue found late.

Our standard MOQs allow this: a verification run at the low end of the tier, then the volume order once the file is closed. Brands transferring an existing EU range from a European manufacturer to China face an additional set of questions around specification transfer and documentation continuity, which we cover in transferring cosmetics production between Europe and China.

A practical audit sequence for your current range

If you are shipping to the EU now and have not reviewed your formulas against this wave, work in this order. It is sequenced by consequence, not by regulation date.

1. Check for the Omnibus VII substances first. Triclocarban, climbazole, 2-chloroacetamide. This has no transition period, so any exposure here is an active problem rather than a scheduled one. Anti-dandruff and antibacterial products are the priority.
2. Calculate Retinol Equivalent on every vitamin A product. Not the raw derivative percentage — the RE conversion. Body lotions are the tight constraint at 0.05%.
3. Check alpha-arbutin levels on face products. 2% ceiling, already in force.
4. Search your INCI lists for cyclotetrasiloxane, cyclopentasiloxane and cyclohexasiloxane. Leave-on hair and colour cosmetics first. June 2027 feels distant until you count backwards through a 60-day reformulation and a packaging cycle.
5. Request updated 82-allergen statements from every fragrance supplier. Scented products, natural fragrances first.
6. Decide harmonise or split for each affected SKU before starting lab work, because the answer changes what we develop.

Steps one to three are the ones with live exposure today. Four and five are scheduled work you can plan into normal production cycles if you start in 2026 rather than 2027.

FAQ

How many cosmetic ingredients are banned in the EU?

Annex II of Regulation (EC) No 1223/2009 lists over 1,700 prohibited substances, and the list grows each year as newly classified CMR substances are added through the Omnibus regulations. Annex III adds several hundred more substances that are permitted only under specific concentration limits and conditions of use. For formulation purposes, the restricted list in Annex III usually matters more day to day than the prohibited list, because that is where concentration caps and product-type conditions sit.

Do I have to withdraw products already on the shelf?

It depends on the instrument. The CMR bans under Regulation (EU) 2025/877 took effect on 1 September 2025 with no transition period, so non-compliant stock is affected immediately. The vitamin A limits under Regulation (EU) 2024/996 applied to new placements from 1 November 2025 and require full withdrawal of non-compliant products by 1 May 2027. The expanded allergen labelling under Regulation (EU) 2023/1545 applies to new products from 31 July 2026 and to all products from 31 July 2028. Check which instrument covers your ingredient before assuming you have a runway.

Can I keep one formula for both the EU and the US?

For most product types, yes — building to the EU standard produces a formula that is compliant in the US, since the EU restrictions are generally stricter. The exceptions are products whose function depends on a substance the EU prohibits outright, such as a 2% hydroquinone lightener, where no compliant EU version exists and a regional split is unavoidable. Scented products now also need market-specific labelling regardless of whether the formula is shared, because US rules still permit a single "fragrance" declaration.

How long does an EU compliance reformulation take?

For a standard cream, lotion, serum or cleanser, 45 to 60 days from brief to production-ready formula: assessment in under a week, lab substitution and trials over two to three weeks, sample approval in one to two weeks, and accelerated stability testing over four to six weeks running in parallel with documentation. Multiple SKUs from the same range share most of the trial work. Formats requiring extended testing, including SPF products and high-oil anhydrous systems, are quoted separately.

Who is responsible if a banned ingredient reaches the EU market?

Under Article 4 of Regulation (EC) No 1223/2009 the Responsible Person established in the EU carries the legal obligation for compliance, which in a private label arrangement is normally the brand or its appointed representative rather than the manufacturer. That said, the manufacturer supplies the specifications and supporting data the Responsible Person relies on. Our position is that the documentation we hand over should let your Responsible Person verify compliance independently rather than take our word for it — if a factory cannot produce that documentation, the exposure sits with you. Our guide to EU compliance for private label cosmetics sets out what the file needs to contain.

Working out your exposure

If you want a formula screened against the current Annex II, Annex III and REACH Annex XVII position, send the full INCI list with product type and target market. We return an assessment identifying which restrictions apply, whether each is a cap or a prohibition, what the substitution route looks like, and what the schedule would be — before any commitment to development work.

Most of the flags brands bring us are manageable inside a normal production cycle. The ones that become expensive are the ones found in 2027 that could have been found in 2026.